Australian molecular Dx firm targets $9.6M in financing

08/2/2013 | GenomeWeb Daily News (free registration)

Genetic Technologies is looking to obtain about $9.6 million through an offering of its company stock. The Australian molecular diagnostics company will use part of the proceeds from the offering to extend the U.S. reach of its BrevaGen test, which is used to diagnose breast cancer.

View Full Article in:

GenomeWeb Daily News (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Executive Officer
Center for Improving Value in Healthcare
Denver, CO
Quality Program Manager II, State Programs
Tufts Health Plan
Watertown, MA
Associate Director, Promotion Integrity
Bristol-Myers Squibb
Plainsboro, NJ
Vice President, Medicare Advantage
Baton Rouge, LA
Director, Global Integrity and Compliance, Pharmaceuticals
Fort Worth, TX